Cube Dx hybcell technology

CUBE DX

UNIQUE CYLINDRICAL MICROARRAY
THERAPY CENTERED DIAGNOSTICS

Innovation for the benefit of patients, clinicians and healthcare payers.

»HOMECOMPANY

Cube Dx

focusses on multiplex tests for routine use in clinical laboratories. Multiplex diagnostics provide parallel evidence of a number of different characteristics (bacteria, gene mutations, inflammatory biomarkers, etc.) in a single test, requiring only minimal amount of sample.

hybcell - the world's unique cylindrical microarray - delivers speedy and reliable results at minimal effort. The hyborg  - the completely automatic device - carries out the processing of the protocol without any intervention by the user. 

Cube Dx is dedicated to provide solutions for unmet medical / diagnostics needs especially in the fields of severe infections. Our team of specialist in (molecular) diagnostics and engineering is convinced that our products contribute to an advancement of modern medicine and thus in the well-being of patients.


 

Meet us

Meet us next...

...at the European Students Conference (www.esc-berlin.com) in Berlin. Cube Dx presents its Integrated Sepsis Diagnostics during a focussed industry exhibition and seminar on 29th of September, 2016. Make sure to be there. If you want to meet, make an appointment using info@cubedx.com!

News Ticker

Latest News...

We believe that the simultaneous (and parallel) measurement and evaluation of a set of biomarkers could improve the quality of clinical decisions of sepsis treatment. At ANESTHESIOLOGY® 2015, organised by the American Society of Anesthesiologists, a first study dealing with the quality of prognosis for single inflammatory and kidney markers in comparison to a combination of two of these markers was presented. The study was carried out by the Clinics of the Ludwig-Maximilians-University, Munich in collaboration with Clinic Neuperlach of the Municipal Hospital Munich.

The authors conclude that a combination of an inflammatory and a kidney biomarker leads to a significantly better prognosis than the use of single biomarkers, and can therefore more readily identify patients that are most critically affected by the disease. The authors recommend the simultaneous measurement of biomarkers to stratify a patient’s risk to die or of suffering critical kidney failure.